-
27
2020-09On September 23, Deloitte, one of the big 4 accounting firms, announced the winners of “2020 Deloitte – Optics Valley Technology Fast 20 and Deloitte – Optics Valley Rising Star” in Shanghai. Brav··· -
16
2020-097 candidates, after several rounds of internal competition and selection, successfully obtained on-the-job training opportunities funded by BravoVax. Mr. WANG Wenhao and other 5 have recently started -
11
2020-08On July 30, “2020 Optics Valley Gazelle Enterprises Summit” opened in Wuhan. BravoVax was awarded the title of “Top Ten Optics Valley Gazelle Enterprises Favored by Venture Capital Firms”. -
11
2020-08On August 6, 2020, the “12th Enmore Bio Products Conference 2020” opened in Haikou, capital city of Hainan Province, BravoVax CEO, Dr. Wu Ke, was invited to preside over the conference. -
13
2020-07On July 2 and July 3, 2020, the "VIP 2020 Vaccine Innovation and Process Optimization Forum", organized by Truesaw, a leading solution provider in healthcare industry, was held in Shanghai. -
01
2020-07On June 28, 2020, Mr. Cao Guangjing, Vice Governor of Hubei Province, and leaders of the Provincial Department of Economy and Information Technology, the Health Commission, the Food and Drug Administr -
01
2020-07Recently, 10 patents, “A Combination Vaccine of RSV-PCV and its Preparation Process” and 9 more patents, independently developed and applied by BravoVax, have been granted authorization by the Natio··· -
16
2020-06Recently DCVMN (Developing Country Vaccine Manufacturers Network) announced the 12 appointed members of COVID-19 Committee. Our VP, Dr. DU Linsen, is elected and will participate in the committee meet -
16
2020-06Recently the Ministry of Education of China has approved 12 projects hosted by BravoVax and its partners, Hubei University and Yancheng Institute of Technology. -
02
2020-04Only one week after BravoVax resumed operation, the good news has come. Jointly applied with Chengda Bio, our vaccine candidate, the 13-valent pneumococcal conjugate vaccine (PCV13) has obtained Impli -
23
2020-03After a special and long holiday, Wuhan BravoVax resumed operation on March 23rd. Early from 7:30AM, our employees started to queue up in front of BravoVax building to show health code, get temperatur -
28
2020-01GeoVax Labs, Inc., a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, together with BravoVax, a vaccine developer in Wuhan, China, announced -
03
2019-09In August, BravoVax signed a cooperation agreement with Chengda Bio on 13-valent pneumococcal conjugate vaccine (PCV13) project. Chengda Bio will invest 78,000,000 RMB to promote the IND submission of -
09
2019-08On August 7, the management team from Instituto Butantan, the vaccine giant in Brazil and one of the largest immunobiologicals and biopharmaceuticals producer in the world, visited BravoVax and the tw -
01
2019-07On June 27th, 2019, GE Healthcare held exchange meeting between GE experts and clients in BravoVax building. This meeting focused on hot topics like industry developments, regulatory updates, trends o